Letters
Views

Arq. Bras. Oftalmol. 2024; 87 (4): 10.5935/0004-2749.2021-0358

Total: 3028

A novel agent for myeloma causing toxic keratopathy, belantamab mafodotin: a case report and literature review

Rengin Aslıhan Kurt1; Deniz Gören2; Sehnaz Karadeniz3; Mutlu Arat2; Afsun Sahin4

DOI: 10.5935/0004-2749.2021-0358

1. Department of Ophthalmology, Baskent University Istanbul Hospital, Istanbul, Turkey
2. Department of Hematology, Sisli Florence Nightingale Hospital, Istanbul, Turkey
3. Department of Ophthalmology, Sisli Florence Nightingale Hospital, Istanbul, Turkey
4. Department of Ophthalmology, Koc University Medical School, Istanbul, Turkey

Corresponding author

Rengin Aslıhan Kurt
E-mail: [email protected]

Funding: This study received no specific financial support

Disclosure of potential conflicts of interest: None of the authors have any potential conflicts of interest to disclose

Informed consent was obtained from all patients included in this study


Read in Portuguese Print PDF English
Open Access
Share

How to cite this article:

Kurt RA, Gören D, Karadeniz S, Arat M, Sahin A. Belantamabe-mafodotina, um novo agente para mieloma, causando ceratopatia tóxica: relato de caso e revisão da literatura. Arq. Bras. Oftalmol. 2024;87(4):. 10.5935/0004-2749.2021-0358
Export citation